

Antineoplastic Drugs-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/A296427656DMEN.html

Date: May 2018 Pages: 158 Price: US\$ 2,480.00 (Single User License) ID: A296427656DMEN

Abstracts

Report Summary

Antineoplastic Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antineoplastic Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Antineoplastic Drugs 2013-2017, and development forecast 2018-2023 Main manufacturers/suppliers of Antineoplastic Drugs worldwide, with company and product introduction, position in the Antineoplastic Drugs market Market status and development trend of Antineoplastic Drugs by types and applications Cost and profit status of Antineoplastic Drugs, and marketing status Market growth drivers and challenges

The report segments the global Antineoplastic Drugs market as:

Global Antineoplastic Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America Europe China Japan Rest APAC



Latin America

Global Antineoplastic Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Chemotherapeutic Agents Biological/Immunotherapeutic Agents Personalized Medicine

Global Antineoplastic Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals Clinics Cancer Rehabilitation Centers Ambulatory Surgical Centers

Global Antineoplastic Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Antineoplastic Drugs Sales Volume, Revenue, Price and Gross Margin):

Hoffmann-La Roche Amgen Bristol-Myers Squibb Baxter Healthcare Boehringer Ingelheim Aspen Global Bayer AG Teva pharmaceutical Industries Johnson & Johnson Merc & Co. Pfize Accord Healthcare Genentech Lundbeck AbbVie

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and



individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF ANTINEOPLASTIC DRUGS

- 1.1 Definition of Antineoplastic Drugs in This Report
- 1.2 Commercial Types of Antineoplastic Drugs
- 1.2.1 Chemotherapeutic Agents
- 1.2.2 Biological/Immunotherapeutic Agents
- 1.2.3 Personalized Medicine
- 1.3 Downstream Application of Antineoplastic Drugs
- 1.3.1 Hospitals
- 1.3.2 Clinics
- 1.3.3 Cancer Rehabilitation Centers
- 1.3.4 Ambulatory Surgical Centers
- 1.4 Development History of Antineoplastic Drugs
- 1.5 Market Status and Trend of Antineoplastic Drugs 2013-2023
 - 1.5.1 Global Antineoplastic Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Antineoplastic Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Antineoplastic Drugs 2013-2017
- 2.2 Sales Market of Antineoplastic Drugs by Regions
- 2.2.1 Sales Volume of Antineoplastic Drugs by Regions
- 2.2.2 Sales Value of Antineoplastic Drugs by Regions
- 2.3 Production Market of Antineoplastic Drugs by Regions
- 2.4 Global Market Forecast of Antineoplastic Drugs 2018-2023
- 2.4.1 Global Market Forecast of Antineoplastic Drugs 2018-2023
- 2.4.2 Market Forecast of Antineoplastic Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Antineoplastic Drugs by Types
- 3.2 Sales Value of Antineoplastic Drugs by Types
- 3.3 Market Forecast of Antineoplastic Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY



4.1 Global Sales Volume of Antineoplastic Drugs by Downstream Industry4.2 Global Market Forecast of Antineoplastic Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Antineoplastic Drugs Market Status by Countries
 - 5.1.1 North America Antineoplastic Drugs Sales by Countries (2013-2017)
 - 5.1.2 North America Antineoplastic Drugs Revenue by Countries (2013-2017)
 - 5.1.3 United States Antineoplastic Drugs Market Status (2013-2017)
 - 5.1.4 Canada Antineoplastic Drugs Market Status (2013-2017)
- 5.1.5 Mexico Antineoplastic Drugs Market Status (2013-2017)
- 5.2 North America Antineoplastic Drugs Market Status by Manufacturers
- 5.3 North America Antineoplastic Drugs Market Status by Type (2013-2017)
- 5.3.1 North America Antineoplastic Drugs Sales by Type (2013-2017)
- 5.3.2 North America Antineoplastic Drugs Revenue by Type (2013-2017)

5.4 North America Antineoplastic Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Antineoplastic Drugs Market Status by Countries
- 6.1.1 Europe Antineoplastic Drugs Sales by Countries (2013-2017)
- 6.1.2 Europe Antineoplastic Drugs Revenue by Countries (2013-2017)
- 6.1.3 Germany Antineoplastic Drugs Market Status (2013-2017)
- 6.1.4 UK Antineoplastic Drugs Market Status (2013-2017)
- 6.1.5 France Antineoplastic Drugs Market Status (2013-2017)
- 6.1.6 Italy Antineoplastic Drugs Market Status (2013-2017)
- 6.1.7 Russia Antineoplastic Drugs Market Status (2013-2017)
- 6.1.8 Spain Antineoplastic Drugs Market Status (2013-2017)
- 6.1.9 Benelux Antineoplastic Drugs Market Status (2013-2017)
- 6.2 Europe Antineoplastic Drugs Market Status by Manufacturers
- 6.3 Europe Antineoplastic Drugs Market Status by Type (2013-2017)
 - 6.3.1 Europe Antineoplastic Drugs Sales by Type (2013-2017)
- 6.3.2 Europe Antineoplastic Drugs Revenue by Type (2013-2017)
- 6.4 Europe Antineoplastic Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,



MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Antineoplastic Drugs Market Status by Countries
- 7.1.1 Asia Pacific Antineoplastic Drugs Sales by Countries (2013-2017)
- 7.1.2 Asia Pacific Antineoplastic Drugs Revenue by Countries (2013-2017)
- 7.1.3 China Antineoplastic Drugs Market Status (2013-2017)
- 7.1.4 Japan Antineoplastic Drugs Market Status (2013-2017)
- 7.1.5 India Antineoplastic Drugs Market Status (2013-2017)
- 7.1.6 Southeast Asia Antineoplastic Drugs Market Status (2013-2017)
- 7.1.7 Australia Antineoplastic Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Antineoplastic Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Antineoplastic Drugs Market Status by Type (2013-2017)
- 7.3.1 Asia Pacific Antineoplastic Drugs Sales by Type (2013-2017)
- 7.3.2 Asia Pacific Antineoplastic Drugs Revenue by Type (2013-2017)

7.4 Asia Pacific Antineoplastic Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Antineoplastic Drugs Market Status by Countries
- 8.1.1 Latin America Antineoplastic Drugs Sales by Countries (2013-2017)
- 8.1.2 Latin America Antineoplastic Drugs Revenue by Countries (2013-2017)
- 8.1.3 Brazil Antineoplastic Drugs Market Status (2013-2017)
- 8.1.4 Argentina Antineoplastic Drugs Market Status (2013-2017)
- 8.1.5 Colombia Antineoplastic Drugs Market Status (2013-2017)
- 8.2 Latin America Antineoplastic Drugs Market Status by Manufacturers
- 8.3 Latin America Antineoplastic Drugs Market Status by Type (2013-2017)
- 8.3.1 Latin America Antineoplastic Drugs Sales by Type (2013-2017)
- 8.3.2 Latin America Antineoplastic Drugs Revenue by Type (2013-2017)

8.4 Latin America Antineoplastic Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Antineoplastic Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa Antineoplastic Drugs Sales by Countries (2013-2017)
 - 9.1.2 Middle East and Africa Antineoplastic Drugs Revenue by Countries (2013-2017)



9.1.3 Middle East Antineoplastic Drugs Market Status (2013-2017)

- 9.1.4 Africa Antineoplastic Drugs Market Status (2013-2017)
- 9.2 Middle East and Africa Antineoplastic Drugs Market Status by Manufacturers
- 9.3 Middle East and Africa Antineoplastic Drugs Market Status by Type (2013-2017)
- 9.3.1 Middle East and Africa Antineoplastic Drugs Sales by Type (2013-2017)

9.3.2 Middle East and Africa Antineoplastic Drugs Revenue by Type (2013-2017)9.4 Middle East and Africa Antineoplastic Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTINEOPLASTIC DRUGS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Antineoplastic Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 ANTINEOPLASTIC DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Antineoplastic Drugs by Major Manufacturers
- 11.2 Production Value of Antineoplastic Drugs by Major Manufacturers
- 11.3 Basic Information of Antineoplastic Drugs by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Antineoplastic Drugs Major Manufacturer

11.3.2 Employees and Revenue Level of Antineoplastic Drugs Major Manufacturer 11.4 Market Competition News and Trend

- 11.4.1 Merger, Consolidation or Acquisition News
- 11.4.2 Investment or Disinvestment News
- 11.4.3 New Product Development and Launch

CHAPTER 12 ANTINEOPLASTIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Hoffmann-La Roche
 - 12.1.1 Company profile
 - 12.1.2 Representative Antineoplastic Drugs Product
- 12.1.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Hoffmann-La Roche
- 12.2 Amgen
 - 12.2.1 Company profile



- 12.2.2 Representative Antineoplastic Drugs Product
- 12.2.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Amgen
- 12.3 Bristol-Myers Squibb
- 12.3.1 Company profile
- 12.3.2 Representative Antineoplastic Drugs Product

12.3.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

- 12.4 Baxter Healthcare
- 12.4.1 Company profile
- 12.4.2 Representative Antineoplastic Drugs Product
- 12.4.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Baxter

Healthcare

- 12.5 Boehringer Ingelheim
 - 12.5.1 Company profile
 - 12.5.2 Representative Antineoplastic Drugs Product
- 12.5.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 12.6 Aspen Global
 - 12.6.1 Company profile
 - 12.6.2 Representative Antineoplastic Drugs Product
- 12.6.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Aspen Global
- 12.7 Bayer AG
 - 12.7.1 Company profile
 - 12.7.2 Representative Antineoplastic Drugs Product
- 12.7.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
- 12.8 Teva pharmaceutical Industries
 - 12.8.1 Company profile
 - 12.8.2 Representative Antineoplastic Drugs Product
- 12.8.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Teva
- pharmaceutical Industries
- 12.9 Johnson & Johnson
- 12.9.1 Company profile
- 12.9.2 Representative Antineoplastic Drugs Product
- 12.9.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

12.10 Merc & Co.

- 12.10.1 Company profile
- 12.10.2 Representative Antineoplastic Drugs Product
- 12.10.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Merc & Co.



12.11 Pfize

- 12.11.1 Company profile
- 12.11.2 Representative Antineoplastic Drugs Product
- 12.11.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Pfize
- 12.12 Accord Healthcare
 - 12.12.1 Company profile
 - 12.12.2 Representative Antineoplastic Drugs Product
- 12.12.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Accord Healthcare
- 12.13 Genentech
- 12.13.1 Company profile
- 12.13.2 Representative Antineoplastic Drugs Product
- 12.13.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Genentech
- 12.14 Lundbeck
 - 12.14.1 Company profile
 - 12.14.2 Representative Antineoplastic Drugs Product
- 12.14.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Lundbeck
- 12.15 AbbVie
 - 12.15.1 Company profile
 - 12.15.2 Representative Antineoplastic Drugs Product
 - 12.15.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of AbbVie

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTINEOPLASTIC DRUGS

- 13.1 Industry Chain of Antineoplastic Drugs
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTINEOPLASTIC DRUGS

- 14.1 Cost Structure Analysis of Antineoplastic Drugs
- 14.2 Raw Materials Cost Analysis of Antineoplastic Drugs
- 14.3 Labor Cost Analysis of Antineoplastic Drugs
- 14.4 Manufacturing Expenses Analysis of Antineoplastic Drugs

CHAPTER 15 REPORT CONCLUSION



CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
- 16.2.2 Primary Sources
- 16.3 Reference



I would like to order

Product name: Antineoplastic Drugs-Global Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/A296427656DMEN.html</u>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A296427656DMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970